Evaluation of MiRNA 223/125a and COBLL1 Expressions and ROR-1 Levels As Reliable Markers in B- Chronic Lymphocytic Leukemia

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2022 Aug 29

PMID 36037128

Authors

Samia Hussein

Abdallah S Abdelazem

Shimaa Abdelmoneem

Al-Shabrawy M Abdelnabi

Tarek Khamis

Ahmed Ali Obaya

Huda F Ebian

Affiliations

Soon will be listed here.

Abstract

Background: miRNA 223 /125a and Cordon-bleu Protein Like 1 (COBLL1) are novel biomarkers that can predict prognosis and guide treatment decisions in patients with chronic lymphocytic leukemia (CLL). Also, there is a growing interest in CLL monitoring based on flow cytometry of receptor tyrosine kinase-like orphan receptor-1 (ROR-1). Objective: This study aimed to evaluate the relationship between miRNA 223 /125a and COBLL1 expressions and ROR-1 expression in patients with CLL. Also, the study evaluated the relationship between the expression of these biomarkers with tumor staging and cancer progression.

Methods: Our study included 40 patients newly diagnosed with B-CLL. In peripheral blood (PB), miRNA 223/125a and COBLL1 expressions were detected by real-time polymerase chain reaction (real-time PCR) and ROR-1 percentage was detected by flow cytometry before and after treatment. Results: High level of COBLL1 expression was statistically significantly associated with high ROR-1 percentage expression (P= 0.03). However, a high level of miRNA 223/125a expression was statistically significantly associated with low ROR-1 percentage expression (P=0.002). The sensitivity and specificity of ROR-1 as a predictor of high WBCs count after treatment were 96.6 and 81.1%, respectively. There was a statistically significant reduction of ROR-1 percentage after treatment compared to before treatment (P <0.001).

Conclusion: ROR-1 percentage expression can be considered a possible prognostic predictor in CLL along with miRNA 223/125a and COBLL1 expressions. This can be explained by the significant correlation between ROR-1 and the studied molecular biomarkers; miRNA 223/125a and COBLL1. In addition, there was a significantly higher ROR-1 percentage in patients with higher WBC counts. Moreover, there was a significant reduction in ROR-1 percentage after treatment.

Citing Articles

MicroRNAs: Potential prognostic and theranostic biomarkers in chronic lymphocytic leukemia.

Ali A, Mahla S, Reza V, Hossein A, Bahareh K, Mohammad H EJHaem. 2024; 5(1):191-205.

PMID: 38406506 PMC: 10887358. DOI: 10.1002/jha2.849.

Gene-Nutrient Interactions in Obesity: Genetic Variants Interact with Dietary Fat Intake to Modulate the Incidence of Obesity.

Kwak J, Shin D Int J Mol Sci. 2023; 24(4).

PMID: 36835164 PMC: 9959357. DOI: 10.3390/ijms24043758.

References

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

Rodriguez-Vicente A, Quwaider D, Benito R, Misiewicz-Krzeminska I, Hernandez-Sanchez M, Garcia de Coca A . MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. BMC Cancer. 2015; 15:238. PMC: 4404064. DOI: 10.1186/s12885-015-1212-2. View

Bilous N, Abramenko I, Chumak A, Dyagil I, Martina Z . Analysis of LPL gene expression in patients with chronic lymphocytic leukemia. Exp Oncol. 2019; 41(1):39-45. View

Janovska P, Poppova L, Plevova K, Plesingerova H, Behal M, Kaucka M . Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2015; 22(2):459-69. PMC: 4716000. DOI: 10.1158/1078-0432.CCR-15-0154. View

Rigolin G, Saccenti E, Rizzotto L, Ferracin M, Martinelli S, Formigaro L . Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients. Oncotarget. 2013; 5(1):140-9. PMC: 3960196. DOI: 10.18632/oncotarget.1382. View

Balatti V, Tomasello L, Rassenti L, Veneziano D, Nigita G, Wang H . and expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood. 2018; 132(20):2179-2182. PMC: 6238191. DOI: 10.1182/blood-2018-04-845115. View

Kim M, Kasinski A, Slack F . MicroRNA therapeutics in preclinical cancer models. Lancet Oncol. 2011; 12(4):319-21. DOI: 10.1016/S1470-2045(11)70067-5. View

Strati P, Jain N, OBrien S . Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clin Proc. 2018; 93(5):651-664. DOI: 10.1016/j.mayocp.2018.03.002. View

Cui B, Ghia E, Chen L, Rassenti L, DeBoever C, Widhopf 2nd G . High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016; 128(25):2931-2940. PMC: 5179332. DOI: 10.1182/blood-2016-04-712562. View

10.

Catovsky D, Richards S, Matutes E, Oscier D, Dyer M, Bezares R . Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007; 370(9583):230-239. DOI: 10.1016/S0140-6736(07)61125-8. View

11.

Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van den Neste E, Michaux L . microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 2009; 113(21):5237-45. DOI: 10.1182/blood-2008-11-189407. View

12.

Plesingerova H, Janovska P, Mishra A, Smyckova L, Poppova L, Libra A . Expression of encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia. Haematologica. 2017; 103(2):313-324. PMC: 5792276. DOI: 10.3324/haematol.2017.178699. View

13.

Zhou K, Yi S, Yu Z, Li Z, Wang Y, Zou D . MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2011; 53(6):1155-61. DOI: 10.3109/10428194.2011.642303. View

14.

Han S, Kim S, Kim H, Lee Y, Choi S, Park G . Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia. Leukemia. 2017; 31(7):1532-1539. DOI: 10.1038/leu.2017.72. View

15.

Davari N, Ahmadpour F, Kiani A, Azadpour M, Tahannejad Asadi Z . Evaluation of microRNA-223 and microRNA-125a expression association with STAT3 and Bcl2 genes in blood leukocytes of CLL patients: a case-control study. BMC Res Notes. 2021; 14(1):21. PMC: 8095339. DOI: 10.1186/s13104-020-05428-0. View

16.

Shahjahani M, Abroun A, Saki N, Bagher Mohammadi S, Rezaeeyan H . STAT5: From Pathogenesis Mechanism to Therapeutic Approach in Acute Leukemia. Lab Med. 2019; 51(4):345-351. DOI: 10.1093/labmed/lmz074. View

17.

Fan Z, Cui H, Xu X, Lin Z, Zhang X, Kang L . MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3. Oncotarget. 2015; 6(28):25266-80. PMC: 4694830. DOI: 10.18632/oncotarget.4457. View

18.

Yu J, Chen L, Cui B, Widhopf 2nd G, Shen Z, Wu R . Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2015; 126(2):585-98. PMC: 4731190. DOI: 10.1172/JCI83535. View

19.

Ahmadvand M, Eskandari M, Khakpour G, Pashaiefar H, Manoochehrabadi S, Yaghmaie M . Identification of MiR-125a as a Novel Plasma Diagnostic Biomarker for Chronic Lymphoblastic Leukemia. Clin Lab. 2019; 65(3). DOI: 10.7754/Clin.Lab.2018.180815. View

20.

De Propris M, Intoppa S, Milani M, Mariglia P, Nardacci M, Peragine N . ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia. Br J Haematol. 2020; 190(6):e346-e349. DOI: 10.1111/bjh.16910. View